ELDNライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:27):

Stats
本日の出来高	91 538.00
平均出来高	89 427.00
時価総額	54.20M
EPS	$0 ( 2024-04-04 )
次の収益日	( $-0.370 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.370
ATR14	$0.0140 (0.63%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-02	Robinson James A. Jr.	Buy	150 437	Stock Option (Right to Buy)
2023-10-02	Kirk Allan	Buy	150 437	Stock Option (Right to Buy)
2023-10-01	Robinson James A. Jr.	Buy	0
2023-10-02	Kirk Allan	Buy	0
2023-05-05	Bvf Partners L P/il	Buy	3 084 090	Warrants to Purchase Common Stock

INSIDER POWER
100.00
Last 95 transactions
Buy: 17 704 764 \| Sell: 1 858 032

ボリューム相関

長: 0.11 (neutral)

短: -0.45 (neutral)

Signal:(62.709) Neutral

Eledon Pharmaceuticals, 相関

10 最も正の相関
GLPG	0.883
HAIN	0.848
NSTG	0.845
ONEM	0.844
RMRM	0.842
CLLS	0.841
FREQ	0.833
SOPA	0.832
MLAB	0.825
AIHS	0.825

10 最も負の相関
ACLS	-0.87
RDI	-0.865
INOD	-0.859
DMAC	-0.851
SPSC	-0.849
IESC	-0.846
CTLP	-0.845
NVTS	-0.844
VRRM	-0.84
ALOR	-0.84

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Eledon Pharmaceuticals, 相関 - 通貨/商品

0.29
( neutral )

0.71
( moderate )

0.00
( neutral )

Eledon Pharmaceuticals, 財務諸表

Annual	2023
収益:	$0
総利益:	$-374 000 (0.00 %)
EPS:	$-1.640

FY	2023
収益:	$0
総利益:	$-374 000 (0.00 %)
EPS:	$-1.640

FY	2022
収益:	$0
総利益:	$-373 000 (0.00 %)
EPS:	$-6.13

FY	2021
収益:	$120 000
総利益:	$120 000 (100.00 %)
EPS:	$-17.31

Financial Reports:

No articles found.

Eledon Pharmaceuticals,

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.